Xena, I don't believe this is about holding Anavex to any other company's standards. I agree with the poster that a brief email from the CEO letting us know that the company is holding up well, or not, under the circumstances is a simple and not too demanding task. It is called Investor Relations.
As I stated in a prior post, the pandemic is not going to alter the long-term result, the drug either works or it does not. However, this is a good opportunity for Dr. M. to reset expectations in regards to time line or to reassure investors if there is no change to already stated milestones. It is the least we should expect from our CEO, whom I believe has done a tremendous job otherwise.
News 
Market Data 
Discover 
